TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Avadel Pharmaceuticals ( (AVDL) ) is now available.
On November 17, 2025, Avadel Pharmaceuticals announced that its Board of Directors has deemed an unsolicited proposal from H. Lundbeck A/S to acquire Avadel as a ‘Company Superior Proposal.’ The Lundbeck proposal values Avadel at up to $23.00 per ordinary share, totaling approximately $2.4 billion, and represents a 29% premium over Avadel’s closing price before the announcement of its acquisition by Alkermes. Avadel has notified Alkermes of this determination, triggering a five-day period for potential negotiations with Alkermes to amend their existing transaction agreement. During this period, Avadel’s Board will evaluate any revised proposal from Alkermes before making a final decision. Currently, no action is required from Avadel shareholders, and the Alkermes Transaction Agreement remains in effect.
The most recent analyst rating on (AVDL) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals’ stock score is primarily driven by strong financial performance improvements and positive earnings call sentiment. However, the stock’s valuation is a significant concern due to negative earnings and lack of dividends. Technical indicators show bullish momentum, but overbought conditions suggest caution. Overall, the stock presents a mixed outlook with potential for growth if profitability improves.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to improve patients’ lives. The company develops innovative medications, including its commercial product LUMRYZ™, which is approved by the U.S. FDA for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older.
Average Trading Volume: 2,646,618
Technical Sentiment Signal: Buy
Current Market Cap: $2.3B
For an in-depth examination of AVDL stock, go to TipRanks’ Overview page.